ISELIN, N.J., Oct. 21, 2015 /PRNewswire/ -- Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company focused on non-invasive continuous glucose monitoring and associated technologies, today announced that it was informed that, due to network scheduling issues, its President and CEO, Scott W. Hollander, is now scheduled to appear on Worldwide Business with kathy ireland, as sponsored programming, on Sunday, October 25, 2015. Echo has accepted this change because it believes that the new day and time will provide increased viewership among key demographics.
Mr. Hollander discusses the benefits of Echo's continuous glucose monitoring (CGM) system, in both the diabetes and the health and wellness markets, with 'Worldwide Business with kathy ireland' host, Kathy Ireland. Worldwide Business with kathy ireland has rescheduled the air date of Mr. Hollander's interview, and it can now be seen on the following date and time:
Sunday, October 25, 2015
Fox Business Network – 11:30am ET
Following the airdate, the segment can be viewed in the Events section of Echo's website at www.echotx.com.
"We are thrilled to have our continuous glucose monitoring technology profiled on Worldwide Business with kathy ireland and to share the benefits of our technology with the program's large global audience," stated Mr. Hollander. "We welcome the exposure that Worldwide Business with kathy ireland provides to our technology, the hope it may give to diabetics and others concerned with their wellness, and the potential value it can bring to our shareholders."
"We seek out companies such as Echo Therapeutics to bring our viewers the latest in innovative solutions and transformative technologies. This useful product certainly fits into that category," added JL Haber, the Vice President of Programming of Worldwide Business with kathy ireland.
About Echo Therapeutics
Echo Therapeutics is developing its non-invasive, wireless, continuous glucose monitoring (CGM) system. A significant opportunity exists for the Company's CGM to be used in the outpatient diabetes market and in the fitness, weight loss and personal lifestyle wearable-health space. A longer-term opportunity also exists in the hospital settings. Echo developed its needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose, and enhanced delivery of topical pharmaceuticals.
About Worldwide Business with kathy ireland ®
Worldwide Business with kathy ireland is a weekly business television program featuring real-world insights from corporate executives from all over the globe.
Worldwide Business with kathy ireland airs Saturday and Sunday evenings throughout North America on Fox Business Network as part of their sponsored programming lineup and to over 50 countries throughout the world on Bloomberg International as part of their sponsored programming lineup.
Cautionary Statement Regarding Forward Looking Statements
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's clinical studies, the safety and efficacy of Echo's CGM System, the failure of future development and preliminary marketing efforts related to Echo's CGM System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell Echo's CGM System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its CGM System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2014, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.
For More Information:
Christine H. Olimpio
Director, Investor Relations and Corporate Communications
SOURCE Echo Therapeutics, Inc.